

# GAUGING *the* GUIDELINES

## Co-Chairs



**Milan Gupta,**  
MD, FRCPC, FACC

Associate Clinical Professor of Medicine, McMaster University  
Assistant Professor of Medicine, University of Toronto  
Medical Director, Canadian Collaborative Research Network



**James A. Stone,**  
BPHE, BA, MSc, MD, PhD, FRCPC, FAACVPR, FACC

Clinical Professor of Medicine  
University of Calgary

## Planning Committee



**Marla Shapiro,**  
CM, CCFP, MHSC, FRCPC, FCFP, NCMP

Associate Professor, DFCM  
University of Toronto



**Ajay Kapur,**  
MD, FRCPC

Clinical Instructor  
University of Toronto

## Accreditation

### College of Family Physicians of Canada – Mainpro+:

This Group Learning program meets the certification criteria of the College of Family Physicians of Canada and has been certified by Continuing Professional Development, Faculty of Medicine, University of Toronto for up to 5.0 Mainpro+ credits.

### Royal College of Physicians and Surgeons of Canada – Section 1:

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, approved by Continuing Professional Development, Faculty of Medicine, University of Toronto. You may claim a maximum of 5 hours (credits are automatically calculated).

## CARDIOVASCULAR Which road to take?

**Saturday, February 25, 2017**

**Mississauga Convention Centre 75 Derry Road West, Mississauga, ON L5W 1G3**

## Agenda

9:00 am	<b>Welcome</b>	Milan Gupta
9:10 am	<b>Debate: Guidelines dissemination should be free of pharma funding</b> • Pro • Con	David Alter Robert Hegele
9:30 am	<b>Atrial Fibrillation Update</b> <b>Debate: Stable Warfarin treated patients should be switched to NOAC</b> • Pro • Con	Paul Dorian Andrew Ha
10:00 am	<b>Q &amp; A</b>	
10:20 am	<b>Health Break</b>	
10:50 am	<b>Heart Failure Update</b> <b>Debate: Sacubitril/Valsartan and Ivabridine in heart failure</b> • Pro - The case for Sacubitril/Valsartan • Con - The case for Ivabridine	Sean Virani Peter Liu
11:20 am	<b>Diabetes Update</b> <b>Debate: Metformin should remain the first line agent</b> • Pro • Con	Amir Hanna Ravi Retnakaran
11:50 am	<b>Q &amp; A</b>	
12:10 pm	<b>Lunch</b>	
1:10 pm	<b>Plenary Lecture: The CV Effects of Cancer and Cancer Therapies</b>	Sean Virani
1:30 pm	<b>Q &amp; A</b>	
1:40 pm	<b>Plenary Lecture: Can you trust guidelines? Pearls for the clinician</b>	Sanjay Kaul
2:00 pm	<b>Q &amp; A</b>	
2:10 pm	<b>Lipids Update</b> <b>Debate: The LDL target in high risk patients should be &lt;1.5</b> • Pro • Con	Milan Gupta Robert Hegele
2:40 pm	<b>Hypertension Update</b> <b>Debate: SBP &lt;120 should be the target for most patients with hypertension</b> • Pro • Con	Sheldon Tobe James Stone
3:10 pm	<b>Q &amp; A</b>	
3:30 pm	<b>Closing Remarks / Close</b>	James Stone

**NOW ACCREDITED**

## The registration fee is \$175

Covers attendance at the full day program, meeting materials, all meals, refreshments and parking.

Registration is to be completed online at: [www.ccrnmd.com](http://www.ccrnmd.com)

For questions please contact  
**Melinda Jones at CCRN:**  
**(905) 453-8885 or**  
[mjones@ccrnm.com](mailto:mjones@ccrnm.com)

